PRESS ANNOUNCEMENT
15 May 2025
Nottingham, UK – BHR Biosynex is delighted to introduce the RevDx portable full blood count POCT system to the UK point-of-care community at this year’s Clinical Innovations Expo, taking place today in Nottingham. This marks the UK debut of the groundbreaking diagnostic platform, designed and manufactured by EfA Technologies, and represents a major step forward in accessible, real-time haematology testing at the point of care.
RevDx is a compact, easy-to-use, all-in-one diagnostic device capable of delivering essential haematology test results within minutes using only a small drop of blood. Built for use in a wide range of clinical environment, from primary care to remote and low-resource settings, RevDx empowers clinicians with rapid, accurate insights to support immediate decision-making, enhance patient outcomes, and streamline clinical workflows. By decentralising diagnostics, RevDx helps reduce laboratory dependency and enables early intervention, especially critical for managing conditions such as anaemia, infections, and blood disorders.
Wendy Thompson, Head of Marketing at BHR Biosynex, shared her enthusiasm about the new product introduction:
“We’re incredibly proud to unveil RevDx for the first time in the UK at the Clinical Innovations Expo. This event is the ideal platform to introduce such a transformative solution, and we’re really looking forward to getting initial feedback from delegates about how RevDx could support their practice and improve patient care.”
Joining the BHR Biosynex team at the Expo is Yoel Ezra, founder and CEO of EfA Technologies, the creators of the RevDx system.
“It’s an honour to be here in the UK and to showcase RevDx to such an engaged and forward-thinking audience,” said Ezra. “We’ve designed RevDx to make haematology testing more accessible and impactful, and we’re excited to see how it can support clinicians across the UK.”
Speak to your BHR Biosynex account manager or email info@bhr.co.uk for more information.
